Dolby Laboratories Financial Statements (DLB) |
||||||||||
Dolby Laboratoriessmart-lab.ru | % | 2021 | 2022 | 2022 | 2023 | 2024 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 17.11.2021 | 30.09.2022 | 18.11.2022 | 17.11.2023 | 19.11.2024 | 19.11.2024 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 1 281 | 1 254 | 1 254 | 1 274 | 1 274 | ||||
Operating Income, bln rub | 344.4 | 206.6 | 206.6 | 258.3 | 257.0 | |||||
EBITDA, bln rub | ? | 464.1 | 320.9 | 329.9 | 258.3 | 342.3 | ||||
Net profit, bln rub | ? | 310.2 | 184.1 | 184.1 | 360.6 | 261.8 | ||||
OCF, bln rub | ? | 447.8 | 318.6 | 318.6 | 327.3 | 327.3 | ||||
CAPEX, bln rub | ? | 54.5 | 47.9 | 59.5 | 30.0 | 30.0 | ||||
FCF, bln rub | ? | 393.3 | 270.6 | 259.1 | 297.2 | 297.2 | ||||
Dividend payout, bln rub | 89.2 | 100.1 | 100.1 | 114.6 | 114.6 | |||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
Dividend payout ratio, % | 28.7% | 54.4% | 54.4% | 31.8% | 43.8% | |||||
OPEX, bln rub | 810.5 | 905.8 | 895.2 | 868.5 | 876.2 | |||||
Cost of production, bln rub | 130.0 | 141.4 | 141.4 | 140.5 | 140.5 | |||||
R&D, bln rub | 253.6 | 261.2 | 261.2 | 263.7 | 263.7 | |||||
Interest expenses, bln rub | 0.479 | 0.394 | 0.394 | 34.1 | 0.000 | |||||
Assets, bln rub | 3 106 | 2 690 | 2 690 | 2 980 | 3 110 | 3 110 | ||||
Net Assets, bln rub | ? | 2 598 | 2 246 | 2 246 | 2 355 | 2 477 | 2 477 | |||
Debt, bln rub | 72.1 | 50.9 | 50.9 | 50.6 | 47.0 | 47.0 | ||||
Cash, bln rub | 1 264 | 809.3 | 809.3 | 884.5 | 482.0 | 577.8 | ||||
Net debt, bln rub | -1 192 | -758.4 | -758.4 | -833.9 | -435.1 | -530.8 | ||||
Ordinary share price, rub | 92.5 | 65.2 | 65.2 | 79.3 | 75.6 | 83.5 | ||||
Number of ordinary shares, mln | 101.2 | 100.0 | 100.0 | 95.5 | 95.4 | |||||
Market cap, bln rub | 9 357 | 6 514 | 6 514 | 0 | 7 224 | 7 961 | ||||
EV, bln rub | ? | 8 165 | 5 756 | 5 756 | -834 | 6 789 | 7 430 | |||
Book value, bln rub | 2 134 | 2 246 | 1 769 | 1 779 | 1 509 | 1 509 | ||||
EPS, rub | ? | 3.07 | 1.84 | 1.84 | 3.77 | 2.74 | ||||
FCF/share, rub | 3.89 | 2.71 | 2.59 | 3.11 | 3.12 | |||||
BV/share, rub | 21.1 | 22.5 | 17.7 | 15.8 | 15.8 | |||||
EBITDA margin, % | ? | 36.2% | 25.6% | 26.3% | 20.3% | 26.9% | ||||
Net margin, % | ? | 24.2% | 14.7% | 14.7% | 28.3% | 20.6% | ||||
FCF yield, % | ? | 4.20% | 4.15% | 3.98% | 0.00% | 4.11% | 3.73% | |||
ROE, % | ? | 11.9% | 8.20% | 8.20% | 0.00% | 14.6% | 10.6% | |||
ROA, % | ? | 9.99% | 6.84% | 6.84% | 0.00% | 11.6% | 8.42% | |||
P/E | ? | 30.2 | 35.4 | 35.4 | 20.0 | 30.4 | ||||
P/FCF | 23.8 | 24.1 | 25.1 | 24.3 | 26.8 | |||||
P/S | ? | 7.30 | 5.20 | 5.20 | 5.67 | 6.25 | ||||
P/BV | ? | 4.38 | 2.90 | 3.68 | 0.00 | 4.79 | 5.27 | |||
EV/EBITDA | ? | 17.6 | 17.9 | 17.4 | 26.3 | 21.7 | ||||
Debt/EBITDA | -2.57 | -2.36 | -2.30 | -1.68 | -1.55 | |||||
R&D/CAPEX, % | 465.8% | 544.9% | 439.3% | 878.7% | 878.7% | |||||
CAPEX/Revenue, % | 4.25% | 3.82% | 4.74% | 2.36% | 2.36% | |||||
Dolby Laboratories shareholders |